GlassScriptPhysician profile
Mirnela Byku
NPI 1891011219
$61,711.79
in general payments reported to CMS, 2019-2025
17 companies · $3,418 in 2025
The $3,418 reported for 2025 was more than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
See the full distribution for Advanced Heart Failure and Transplant Cardiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $4,143 · 2021: $2,822 · 2022: $24K · 2023: $12K · 2024: $4,536 · 2025: $3,418.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $15K · Travel and Lodging: $2,496 · Food and Beverage: $2,291.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $15,225.00 |
| Travel and Lodging | $2,495.87 |
| Food and Beverage | $2,291.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $38,379.24 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Alnylam Pharmaceuticals INC. | $18,556.99 | 2019-2022 | |
| Akcea Therapeutics, INC. | $3,187.48 | 2020 | |
| Pfizer INC. | $717.39 | 2020-2025 | |
| Medtronic Vascular, INC. | $275.17 | 2019 | |
| Biotronik INC. | $192.84 | 2019-2022 | |
| Cvrx, INC. | $149.21 | 2023-2025 | Barostim Neo System |
| Abiomed | $98.79 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $95.64 | 2023 | Lifevest |
| Medtronic, INC. | $27.94 | 2022 | |
| Novartis Pharmaceuticals Corporation | $17.21 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $13.89 | 2022 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mirnela Byku listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.